Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes engineered biosynthetic pathways, recombinant cells, and methods relating to biosynthesis of esters. The recombinant cells may be modified to exhibit increased biosynthesis of an ester compared to a wild-type control. The recombinant cell may be incubated in medium that includes a carbon source under conditions effective for the recombinant cell to produce an ester. This disclosure also describes a method that generally includes introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes a step in converting a carbon source to an ester, wherein the at least one polynucleotide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to an ester.

Abstract: This disclosure describes a recombinant microbial cells and methods of making and using such recombinant microbial cells. Generally, the recombinant cells may be modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control. In some embodiments, the TCA derivative can include 1,4-butanediol. In various embodiments, the microbial cell is a fungal cell or a bacterial cell. In some embodiments, the increased biosynthesis of the TCA derivative can include an increase in xylose dehydrogenase activity, xylonolactonase activity, xylonate dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.

Abstract: This disclosure describes a recombinant microbial cells and methods of making and using such recombinant microbial cells. Generally, the recombinant cells may be modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control. In some embodiments, the TCA derivative can include 1,4-butanediol. In various embodiments, the microbial cell is a fungal cell or a bacterial cell. In some embodiments, the increased biosynthesis of the TCA derivative can include an increase in xylose dehydrogenase activity, xylonolactonase activity, xylonate dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.

Abstract: This disclosure describes biosynthesized compounds including anhydromevalonolactone and ?-methyl-?-valerolactone. This disclosure further describes biosynthetic methods for making these compounds. In some embodiments, the biosynthetic methods can include a combination of biosynthesis and chemical steps to produce ?-methyl-?-valerolactone. Finally, this disclosure described recombinant cells useful for the biosynthesis of these compounds.

Abstract: This disclosure describes a recombinant microbial cells and methods of making and using such recombinant microbial cells. Generally, the recombinant cells may be modified to exhibit increased biosynthesis of a TCA derivative compared to a wild-type control. In some embodiments, the TCA derivative can include 1,4-butanediol. In various embodiments, the microbial cell is a fungal cell or a bacterial cell. In some embodiments, the increased biosynthesis of the TCA derivative can include an increase in xylose dehydrogenase activity, xylonolactonase activity, xylonate dehydratase activity, or 2-keto-3-deoxyaldonic acid dehydratase activity.

Abstract: This disclosure describes engineered biosynthetic pathways, recombinant cells, and methods relating to biosynthesis of esters. The recombinant cells may be modified to exhibit increased biosynthesis of an ester compared to a wild-type control. The recombinant cell may be incubated in medium that includes a carbon source under conditions effective for the recombinant cell to produce an ester. This disclosure also describes a method that generally includes introducing into a host cell a heterologous polynucleotide encoding at least one polypeptide that catalyzes a step in converting a carbon source to an ester, wherein the at least one polynucleotide is operably linked to a promoter so that the modified host cell catalyzes conversion of the carbon source to an ester.

Abstract: Disclosed herein are cells and methods for renewably producing isobutyrate. In some cases, the cells can include a heterologous DNA that encodes at least one enzyme that catalyzes the conversion of isobutyraldehyde to isobutyrate. In other cases, the cells can include a genetically modified enzyme that catalyzes the conversion of isobutyraldehyde to isobutyrate to a degree greater than the wild-type version of the enzyme. In other cases, the cells can include one or more enzyme that catalyze the conversion of 2-ketovaline to isobutyrate. Generally, methods include growing the cells in a medium that includes a carbon source that the cells are able to convert to isobutyrate.